Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Gastrointestinal Carcinoid TumorIslet Cell Tumor
Interventions
DRUG

capecitabine

DRUG

cisplatin

DRUG

streptozocin

GENETIC

DNA analysis

GENETIC

RNA analysis

GENETIC

protein analysis

GENETIC

proteomic profiling

OTHER

laboratory biomarker analysis

Trial Locations (17)

SS16 5NL

Basildon University Hospital, Basildon

CB2 2QQ

Addenbrooke's Hospital, Cambridge

LS16 6QB

Cookridge Hospital, Leeds

LE1 5WW

Leicester Royal Infirmary, Leicester

L9 7AL

Aintree University Hospital, Liverpool

NW3 2QG

UCL Cancer Institute, London

SE1 7EH

St. Thomas' Hospital, London

ME16 9QQ

Mid Kent Oncology Centre at Maidstone Hospital, Maidstone

M20 4BX

Christie Hospital, Manchester

CH63 4JY

Clatterbridge Centre for Oncology, Merseyside

NE4 6BE

Northern Centre for Cancer Treatment at Newcastle General Hospital, Newcastle upon Tyne

0X3 9DU

Oxford Radcliffe Hospital, Oxford

SM2 5PT

Royal Marsden - Surrey, Sutton

SS0 0RY

Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea

EH4 2XU

Edinburgh Cancer Centre at Western General Hospital, Edinburgh

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

CF14 2TL

Velindre Cancer Center at Velindre Hospital, Cardiff

All Listed Sponsors
lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT00602082 - Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter